Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

TScan Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$0.92

-0.05 (-4.7%)

D 32Pipeline Score Overvalued Biotech · Commercial
Market Cap
69.27 M
EPS
-0.96
P/E Ratio
-
Value Trade
432.01 K
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    982.00 K

  • R&D Expenses

    21.90 M

  • Operating CF

    -24.28 M

  • Total Assets

    201.99 M

  • Total Liabilities

    105.07 M

  • Equity

    96.92 M

  • D/E Ratio

    12,345

-1.85 %
Week
-17.19 %
1 Month
4.95 %
3 Month
8.16 %
6 Month
-91.17 %
5 Year
-91.17 %
All Time
Cash Data
Stable

  • Cash Position

    128.06 M

  • Monthly Burn

    8.09 M

  • Runway

    14.7 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 6, 2026
Overview
Volume
288.83 K
52 Week Range
0.88 - 2.57
% held by Insiders
14.87 %
% held by Institutions
47.86 %
Enterprise Value
33.75 M
Total Shares
52.46 M
Short %
2.19 %
Float Shares
42.76 M
Company Description
HQ: 830 WINTER STREET, WALTHAM, MA...
Employees:142
https://www.tscan.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 1 data readout example
TSC-101 Hematologic malignancies
Phase 1
—
Gene Therapies
Hematologic System
TSC-101 Hematologic malignancies
Phase 1
—
Gene Therapies
Hematologic System
TSC-101 Hematologic malignancies
Phase 1
—
Gene Therapies
Hematologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D32
Pipeline Score
$13M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 36%
Micro Cap
(rank 580 of 905)
Percentile Rank
TScan Therapeutics, Inc. faces pipeline headwinds (32/100), with $259M risk-adjusted pipeline value, led by TSC-204-A0201 in Head and Neck Cancer (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
TSC-204-A0201
Monoclonal antibody		Head and Neck CancerPhase 1NCT0597348717% $259M ACTIVE NOT_RECRUITING 840 VERY_FAST C (53) Dec 30, 2026ELEVATED_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
TSC-101
acute myeloid leukemia (AML),acute lymphoblastic leukemia (ALL),myelodysplastic syndrome (MDS)
Phase 1
2025-08-12
TSC-101
acute myeloid leukemia (AML),acute lymphoblastic leukemia (ALL),myelodysplastic syndrome (MDS)
Phase 1
2025-08-12
TSC-101
acute myeloid leukemia (AML),acute lymphoblastic leukemia (ALL),myelodysplastic syndrome (MDS)
Phase 1
2025-08-12
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TCRX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TCRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TCRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TCRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
TCRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
TCRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest TScan Therapeutics, Inc. (TCRX) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How TCRX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
HPV #4 of 5 PHASE 1 TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-202-A0201
MRK VRCA PGEN
$10.57B 0.76 CONTENDER
Anal Cancer #5 of 5 PHASE 1 TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-202-A0201
PFE INCY IOVA
$0.74B 0.76 CONTENDER
Cervical Cancer #16 of 31 PHASE 1 TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-202-A0201
AZN MRK PFE
$2.8B 0.83 FOLLOWER
Melanoma #29 of 52 PHASE 1 TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-202-A0201
MRK BMY REGN
$10.5B 0.83 FOLLOWER
Head and Neck Cancer #30 of 63 PHASE 1 TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-202-A0201
AZN GSK MRK
$10.2B 0.83 FOLLOWER
Ovarian Cancer #40 of 61 PHASE 1 TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-202-A0201
MRK AZN LLY
$4.0B 0.76 FOLLOWER
Non-Small Cell Lung Cancer #47 of 88 PHASE 1 TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-202-A0201
MRK AMGN AZN
$28.1B 0.83 FOLLOWER